Andres Ricaurte Fajardo on a Strongyloides Stercoralis Hyperinfection with Thrombosis
Andres Ricaurte Fajardo, Neurology resident at University Pontificia Javeriana, shared on LinkedIn:
”I am proud to share our latest systematic review on the underrecognized association between Strongyloides stercoralis hyperinfection syndrome and thrombotic complications published at New Microbes and New Infections (Q2 Journal).
We systematically analyzed 16 reported cases of SHS with thrombosis, highlighting a broad spectrum of events, including deep vein thrombosis, pulmonary embolism, portal and renal vein thrombosis, intracardiac thrombi, thrombotic microangiopathy, and disseminated intravascular coagulation.
Despite treatment with ivermectin-based regimens, mortality exceeded 30%, especially in immunosuppressed patients and those presenting with shock or multifocal thrombosis.
Key Take-Home Messages
Strongyloides hyperinfection should be actively considered in immunosuppressed patients (including those on chronic corticosteroids, chemotherapy, or other immunomodulators) who present with sepsis, shock, or unexplained thrombosis.
Thrombotic involvement in SHS is heterogeneous and often multifocal, affecting venous, arterial, and microvascular territories—including catastrophic presentations such as DIC.
Diagnostic delay is common and frequently related to nonspecific symptoms and the absence of eosinophilia in patients on steroids, contributing to high mortality.
Ivermectin remains the cornerstone of therapy, sometimes combined with albendazole, but treatment regimens are variable; early empiric initiation in high-risk patients is critical.
There is an urgent need for standardized diagnostic approaches, systematic screening in endemic settings, and better reporting of thrombotic outcomes in strongyloidiasis.”
Read the full article here.
Article: Strongyloides stercoralis hyperinfection with thrombosis: A systematic review of case reports
Authors: Darío S. López-Delgado, Carlos A. Narváez, Roberto Bonfante-Villalobos, Joshua Emmanuel Arteaga, Hector Fabio Sanchez-Galvez, Andres Ricaurte Fajardo, Lysien Zambrano, Alfonso J. Rodriguez-Morales
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?